Click on image to view larger version.

Figure 1 Aspirin, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors were less likely to be provided to patients with end-stage renal disease (ESRD) than those without ESRD. In an analysis of patients considered ideal for the individual therapies, the overall administration rates were higher, but patients with ESRD still remained less likely to receive the therapy than those without ESRD. The p value for each comparison between ESRD and non-ESRD patients was <0.001.